InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,709.54
(
0.00%
)
US TECH 100
19,196.00
(
-0.43%
)
Dow Jones
42,196.52
(
0.00%
)
Brent Oil
75.63
(
1.35%
)
Bitcoin
60,005.00
(
-1.02%
)
Post# of 253269
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DewDiligence post# 207055

Sunday, 12/18/2016 12:15:52 AM

Sunday, December 18, 2016 12:15:52 AM

Post# of 253269
>>CHMP conditionally approves Roche’s Alecensa for ALK+ second-line* NSCLC

From a purely medical perspective, it is close to malpractice to use this drug only second line. Much better to use it initially instead of first waiting to develop brain mets on Xalkori.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up